These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 31388782)
1. Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade? Nambirajan A; Malgulwar PB; Sharma A; Boorgula MT; Doddamani R; Singh M; Suri V; Sarkar C; Sharma MC Brain Tumor Pathol; 2019 Oct; 36(4):152-161. PubMed ID: 31388782 [TBL] [Abstract][Full Text] [Related]
2. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin. Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850 [TBL] [Abstract][Full Text] [Related]
3. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470 [TBL] [Abstract][Full Text] [Related]
4. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome. Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114 [TBL] [Abstract][Full Text] [Related]
5. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters. Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576 [TBL] [Abstract][Full Text] [Related]
6. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods. de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940 [TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma. Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834 [TBL] [Abstract][Full Text] [Related]
8. The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study. Wang L; Han S; Yan C; Yang Y; Li Z; Yang Z J Cancer Res Clin Oncol; 2021 Apr; 147(4):1259-1270. PubMed ID: 33387039 [TBL] [Abstract][Full Text] [Related]
9. Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications. Chinnam D; Gupta K; Kiran T; Saraswati A; Salunke P; Madan R; Kumar N; Radotra BD Brain Tumor Pathol; 2022 Jul; 39(3):151-161. PubMed ID: 35348910 [TBL] [Abstract][Full Text] [Related]
10. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K; Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397 [TBL] [Abstract][Full Text] [Related]
12. Molecular subtyping of ependymoma and prognostic impact of Ki-67. Lim KY; Lee K; Shim Y; Park JW; Kim H; Kang J; Won JK; Kim SK; Phi JH; Park CK; Chung CK; Yun H; Park SH Brain Tumor Pathol; 2022 Jan; 39(1):1-13. PubMed ID: 34812989 [TBL] [Abstract][Full Text] [Related]
14. Survival and Prognostic Factors of Adult Intracranial Ependymoma: A Single-institutional Analysis of 236 Patients. Zhao F; Wu T; Wang LM; Zhang J; Zhang H; Li SW; Zhang S; Li P; Wang B; Luo L; Liu PN Am J Surg Pathol; 2021 Jul; 45(7):979-987. PubMed ID: 33739788 [TBL] [Abstract][Full Text] [Related]
15. RELA Fusion in Supratentorial Extraventricular Ependymomas: A Morphologic, Immunohistochemical, and Molecular Study of 43 Cases. Wang L; Liu L; Li H; Wang P; Hu Z; Wei Y; Zhang M; Wen W; Li Z; Liu L; Zhao L; Lu D; Teng L Am J Surg Pathol; 2019 Dec; 43(12):1674-1681. PubMed ID: 31393268 [TBL] [Abstract][Full Text] [Related]
16. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077 [TBL] [Abstract][Full Text] [Related]
17. Supratentorial ependymoma in childhood: more than just RELA or YAP. Zschernack V; Jünger ST; Mynarek M; Rutkowski S; Garre ML; Ebinger M; Neu M; Faber J; Erdlenbruch B; Claviez A; Bielack S; Brozou T; Frühwald MC; Dörner E; Dreschmann V; Stock A; Solymosi L; Hench J; Frank S; Vokuhl C; Waha A; Andreiuolo F; Pietsch T Acta Neuropathol; 2021 Mar; 141(3):455-466. PubMed ID: 33481105 [TBL] [Abstract][Full Text] [Related]
18. epi-Aszonalenin B from Aspergillus novofumigatus inhibits NF-κB activity induced by ZFTA-RELA fusion protein that drives ependymoma. Ishikawa K; Ishii M; Yaguchi T; Katada T; Ichinose K; Ohata S Biochem Biophys Res Commun; 2022 Mar; 596():104-110. PubMed ID: 35131506 [TBL] [Abstract][Full Text] [Related]
19. Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology. Gessi M; Giagnacovo M; Modena P; Elefante G; Gianno F; Buttarelli FR; Arcella A; Donofrio V; Diomedi Camassei F; Nozza P; Morra I; Massimino M; Pollo B; Giangaspero F; Antonelli M Am J Surg Pathol; 2019 Jan; 43(1):56-63. PubMed ID: 29266023 [TBL] [Abstract][Full Text] [Related]
20. Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma. de Almeida Magalhães T; Alencastro Veiga Cruzeiro G; Ribeiro de Sousa G; Englinger B; Fernando Peinado Nagano L; Ancliffe M; Rodrigues da Silva K; Jiang L; Gojo J; Cherry Liu Y; Carline B; Kuchibhotla M; Pinto Saggioro F; Kazue Nagahashi Marie S; Mieko Oba-Shinjo S; Andres Yunes J; Gomes de Paula Queiroz R; Alberto Scrideli C; Endersby R; Filbin MG; Silva Borges K; Salic A; Gonzaga Tone L; Valera ET Neuro Oncol; 2023 Jan; 25(1):185-198. PubMed ID: 35640920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]